Daxor ROCE

Mitä Daxor tekee? Daxor Corp develops and markets the BVA-100 blood volume analyzer, a diagnostic instrument cleared by the FDA for measuring human blood volume. The company sells the BVA-100 to hospital centers across the United States, where over 65,000 tests have been performed to improve surgical and medical outcomes. Hospitals use the device to enhance performance metrics in heart failure and critical care, reducing mortality and readmissions. The company also advances healthcare through blood volume analysis for optimal fluid management, supported by NIH-funded trials in heart failure treatment and ongoing contracts for analyzer development. Daxor Corp's primary revenue comes from the sale of the BVA-100 blood volume analyzer and associated diagnostic services. The device is used in hospital settings to provide objective blood volume measurements, which help clinicians manage fluid therapy more effectively. Over 65,000 tests performed at U.S. hospital centers demonstrate the product's adoption and clinical utility. The company's focus on heart failure and critical care applications aligns with its ongoing NIH-supported trials and development contracts, driving demand for its technology. The firm's key customers are hospital centers in the United States, where the BVA-100 has been integrated into clinical workflows for blood volume analysis. These institutions benefit from reduced mortality and readmissions in heart failure and critical care, as reported in the business description. Daxor Corp generates revenue through direct sales of the analyzer and related services, with additional support from NIH contracts and ongoing development work for blood volume analyzers. Daxor on yksi Eurpooliin suosituimmista yhtiöistä.